Artrya (ASX:AYA) Total Receivables: A$9.22 Mil (As of Dec. 2025)


ASX:AYA Artrya Ltd ASX:AYA
35 GF Score
Price A$6.27
! 1 Warning Sign
View Full Analysis

What is Artrya Total Receivables?

Artrya ASX:AYA +6.09% 35 Total Receivables is A$9.22 Mil as of Dec. 2025. GuruFocus rates ASX:AYA with a GF Score™ of 35/100. The stock has 1 warning sign investors should review.

Artrya's Total Receivables for the quarter that ended in Dec. 2025 was A$9.22 Mil.

Artrya Total Receivables Historical Data

* Premium members only.

The historical data trend for Artrya's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Artrya Total Receivables Chart

Artrya Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Total Receivables
1.43 1.99 3.07 3.87 5.38

Artrya Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.26 3.87 2.05 5.38 9.22
ASX:AYA
35GF Score
Artrya Ltd ASX:AYA
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Artrya Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of A$9.22 Mil mean?
Artrya (ASX:AYA) has a Total Receivables of A$9.22 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Artrya and its competitors.
Is Artrya's Total Receivables too high?
Artrya's current Total Receivables is A$9.22 Mil. Overall, Artrya has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Artrya's Total Receivables compare to VEEV and BTSG?
Artrya's Total Receivables of A$9.22 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Healthcare Providers & Services company?
A good Total Receivables depends on the Healthcare Providers & Services industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Artrya and its competitors. Artrya's current Total Receivables is A$9.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artrya stock overvalued right now?
Artrya (ASX:AYA) has a current Total Receivables of A$9.22 Mil. The current Total Receivables is A$9.22 Mil. Artrya's overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Artrya (ASX:AYA), the current Total Receivables is A$9.22 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Artrya Business Description

Address 1257 Hay Street, West Perth, Perth, WA, AUS, 6005
Artrya Ltd is a medical technology company. The company is engaged in the development and commercialization of Artrya Salix, its patented artificial intelligence platform that detects, diagnoses, and helps address coronary artery disease. It is managed based on a single segment, being the development of AI-driven CCTA image analysis technology.
35GF Score

Get the complete analysis for ASX:AYA

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$6.27
Price